GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medical Developments International Ltd (ASX:MVP) » Definitions » Cash Ratio

Medical Developments International (ASX:MVP) Cash Ratio : 1.41 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Medical Developments International Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Medical Developments International's Cash Ratio for the quarter that ended in Dec. 2023 was 1.41.

Medical Developments International has a Cash Ratio of 1.41. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Medical Developments International's Cash Ratio or its related term are showing as below:

ASX:MVP' s Cash Ratio Range Over the Past 10 Years
Min: 0.13   Med: 1.74   Max: 5.21
Current: 1.41

During the past 13 years, Medical Developments International's highest Cash Ratio was 5.21. The lowest was 0.13. And the median was 1.74.

ASX:MVP's Cash Ratio is ranked better than
71.37% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs ASX:MVP: 1.41

Medical Developments International Cash Ratio Historical Data

The historical data trend for Medical Developments International's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medical Developments International Cash Ratio Chart

Medical Developments International Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.05 1.89 5.21 1.95 1.59

Medical Developments International Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.11 1.95 2.37 1.59 1.41

Competitive Comparison of Medical Developments International's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medical Developments International's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Medical Developments International's Cash Ratio falls into.



Medical Developments International Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Medical Developments International's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=24.661/15.548
=1.59

Medical Developments International's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=15.699/11.156
=1.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medical Developments International  (ASX:MVP) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Medical Developments International Cash Ratio Related Terms

Thank you for viewing the detailed overview of Medical Developments International's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medical Developments International (ASX:MVP) Business Description

Traded in Other Exchanges
N/A
Address
4 Caribbean Drive, Scoresby, VIC, AUS, 3179
Medical Developments International Ltd is a specialized healthcare company. It manufactures and distributes the pharmaceutical drug and medical and veterinary equipment. The company provides a range of products in the areas of pain management, asthma, and resuscitation, plus veterinary equipment. It is organized into three business units: Pharmaceuticals, Medical Devices, and Veterinary products. Majority of its revenue comes from Pharmaceuticals Unit which engages in the sale of Penthrox within Australia, New Zealand, Europe the UK and some sales in Canada, the Middle East, Asia and South Africa.

Medical Developments International (ASX:MVP) Headlines

From GuruFocus

Roundhill Announces Two Fund Closures

By PRNewswire PRNewswire 03-18-2022